CIK 1633313
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 81.96% | 23 |
| Unclassified | 14.24% | 6 |
| Health Care Providers & Services | 3.79% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | UTHR | UNITED THERAPEUTICS Corp | Health Care | 15.36% |
| 2 | ASND | Ascendis Pharma A/S | Health Care | 11.41% |
| 3 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Health Care | 9.38% |
| 4 | KRYS | Krystal Biotech, Inc. | Health Care | 7.35% |
| 5 | ARGX | Argenx SE | Health Care | 7.19% |
| 6 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | Health Care | 6.61% |
| 7 | KYMR | Kymera Therapeutics, Inc. | Health Care | 6.13% |
| 8 | APELLIS PHARMACEUTICALS INC | Unclassified | 4.84% | |
| 9 | CENTESSA PHARMACEUTICALS PLC | Unclassified | 4.47% | |
| 10 | CELC | Celcuity Inc. | Health Care | 3.79% |
24/30 names classified · sector 85.8% of weight · industry 85.8% · mkt cap 67.2%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 85.8% of the book is sector-classified (unclassified names shown, never dropped).
Only 16% of book weight classified — the grid is NOT representative of the whole book.
Classified: 15.9% of book weight (4/27 names) · unclassified 84.1%: , ASND, MDGL, KRYS, ARGX, ARWR, KYMR, CELC, XENE, GPCR +13 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | UTHRUnited Therapeutics Corp. | 2,630,000 | $1.6B | 15.4% | HOLD |
| 2 | ASNDASCENDIS PHARMA A/S | 5,062,500 | $1.2B | 11.4% | HOLD |
| 3 | MDGLMADRIGAL PHARMACEUTICALS INC | 1,818,181 | $952M | 9.4% | HOLD |
| 4 | KRYSKRYSTAL BIOTECH INC | 2,888,888 | $746M | 7.4% | HOLD |
| 5 | ARGXARGENX SE | 1,000,000 | $730M | 7.2% | HOLD |
| 6 | ARWRARROWHEAD PHARMACEUTICALS IN | 10,699,999 | $671M | 6.6% | HOLD |
| 7 | KYMRKYMERA THERAPEUTICS INC | 7,474,747 | $623M | 6.1% | HOLD |
| 8 | APELLIS PHARMACEUTICALS INC | 12,222,222 | $492M | 4.8% | HOLD |
| 9 | CENTESSA PHARMACEUTICALS PLC | 11,430,455 | $454M | 4.5% | TRIM −21% |
| 10 | CELCCELCUITY INC | 3,375,000 | $385M | 3.8% | ADD 8% |
| 11 | XENEXENON PHARMACEUTICALS INC | 5,777,777 | $336M | 3.3% | ADD 7% |
| 12 | GPCRSTRUCTURE THERAPEUTICS INC | 6,555,555 | $316M | 3.1% | HOLD |
| 13 | TERNS PHARMACEUTICALS INC | 5,695,000 | $300M | 3.0% | ADD 31% |
| 14 | VERAVERA THERAPEUTICS INC | 5,888,888 | $237M | 2.3% | HOLD |
| 15 | RVMDREVOLUTION MEDICINES INC | 2,344,444 | $228M | 2.2% | ADD 8% |
| 16 | CYTKCYTOKINETICS INC | 3,333,333 | $220M | 2.2% | NEW |
| 17 | OCULOCULAR THERAPEUTIX INC | 12,315,000 | $104M | 1.0% | ADD 14% |
| 18 | DMRADAMORA THERAPEUTICS INC | 3,783,000 | $98M | 1.0% | NEW |
| 19 | QUREUNIQURE NV | 5,959,595 | $97M | 1.0% | TRIM −3% |
| 20 | TSHATAYSHA GENE THERAPIES INC | 21,700,000 | $97M | 1.0% | HOLD |
| 21 | DFTXDEFINIUM THERAPEUTICS INC COM SHS | 5,000,000 | $95M | 0.9% | NEW |
| 22 | SOLENO THERAPEUTICS INC | 2,300,000 | $77M | 0.8% | TRIM −21% |
| 23 | ALKSALKERMES PLC | 1,200,000 | $42M | 0.4% | TRIM −14% |
| 24 | SEPNSEPTERNA INC | 1,337,500 | $32M | 0.3% | HOLD |
| 25 | VRDNVIRIDIAN THERAPEUTICS INC | 1,500,000 | $29M | 0.3% | HOLD |
| 26 | GHRSGH RESEARCH PLC | 1,800,000 | $25M | 0.2% | HOLD |
| 27 | AVTXAVALO THERAPEUTICS INC | 1,410,000 | $21M | 0.2% | NEW |
| 28 | LXEOLEXEO THERAPEUTICS INC | 1,875,000 | $11M | 0.1% | TRIM −43% |
| 29 | WHWKWHITEHAWK THERAPEUTICS INC | 2,849,402 | $10M | 0.1% | HOLD |
| 30 | MNKDMANNKIND CORP | 2,200,000 | $5M | 0.1% | TRIM −50% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| UTHRUnited Therapeutics Corp. | 2.8M | 2.7M | 2.4M | 2.0M | 2.6M | 2.6M | $1.6B |
| ASNDASCENDIS PHARMA A/S | 5.1M | 5.2M | 5.0M | 5.1M | 5.1M | 5.1M | $1.2B |
| MDGLMADRIGAL PHARMACEUTICALS INC | 2.0M | 2.0M | 1.9M | 1.8M | 1.8M | 1.8M | $952M |
| KRYSKRYSTAL BIOTECH INC | 2.6M | 2.7M | 2.7M | 2.8M | 2.9M | 2.9M | $746M |
| ARGXARGENX SE | 1.2M | 1.2M | 1.2M | 990K | 990K | 1.0M | $730M |
| ARWRARROWHEAD PHARMACEUTICALS IN | 11.1M | 11.1M | 10.6M | 10.9M | 10.6M | 10.7M | $671M |
| KYMRKYMERA THERAPEUTICS INC | 5.2M | 6.5M | 6.6M | 6.3M | 7.5M | 7.5M | $623M |
| APELLIS PHARMACEUTICALS INC | 12.2M | 12.2M | 12.2M | 12.2M | 12.2M | 12.2M | $492M |
| CENTESSA PHARMACEUTICALS PLC | — | 4.0M | 5.0M | 10.8M | 14.6M | 11.4M | $454M |
| CELCCELCUITY INC | — | — | — | — | 3.1M | 3.4M | $385M |
| XENEXENON PHARMACEUTICALS INC | 5.7M | 5.7M | 5.4M | 5.4M | 5.4M | 5.8M | $336M |
| GPCRSTRUCTURE THERAPEUTICS INC | — | — | — | 5.2M | 6.6M | 6.6M | $316M |
| TERNS PHARMACEUTICALS INC | — | — | — | — | 4.3M | 5.7M | $300M |
| VERAVERA THERAPEUTICS INC | 5.6M | 5.7M | 6.3M | 6.2M | 5.9M | 5.9M | $237M |
| RVMDREVOLUTION MEDICINES INC | — | — | — | — | 2.2M | 2.3M | $228M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
